These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8509233)

  • 1. A randomized study of alfacalcidol in the refractory myelodysplastic anaemias. A Japanese cooperative study.
    Yoshida Y; Oguma S; Uchino H; Maekawa T; Nomura T
    Int J Clin Pharmacol Res; 1993; 13(1):21-7. PubMed ID: 8509233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of myelodysplastic syndrome with alfacalcidol].
    Tagawa M; Ito H; Kuriyama K; Tomonaga M; Ichimaru M
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3160-2. PubMed ID: 3674901
    [No Abstract]   [Full Text] [Related]  

  • 3. Conservative treatment of refractory myelodysplastic anemias: a Japanese Cooperative Study.
    Yoshida Y; Yamagishi M; Oguma S; Uchino H; Maekawa T
    Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1448-54. PubMed ID: 3073616
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
    Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
    Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two?
    Ohyashiki K; Yokoyama K; Kimura Y; Ohyashiki JH; Ito T; Kuratsuji T; Komatsumoto S; Nara M; Toyama K
    Leukemia; 1993 Feb; 7(2):338-40. PubMed ID: 8426488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
    Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
    Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic effectiveness of vitamin D3 in patients with myelodysplastic syndromes, leukemias and myeloproliferative disorders].
    Takahashi T; Ichiba S; Okuno Y; Sugiyama H; Sakai Y; Imura H; Iho S; Hoshino T; Suzuki A; Okada T
    Rinsho Ketsueki; 1989 Jan; 30(1):1-10. PubMed ID: 2716194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
    Reichel H
    Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 (1 alpha(OH)D3)].
    Taoka T; Hamamoto T; Okuda Y; Hata Y; Kubota Y; Tanaka T; Irino S; Miyazaki T; Ohbayashi S
    Rinsho Ketsueki; 1987 Jun; 28(6):830-8. PubMed ID: 3478504
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
    Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
    Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Schouten HC; Vellenga E; van Rhenen DJ; de Wolf JT; Coppens PJ; Blijham GH
    Leukemia; 1991 May; 5(5):432-6. PubMed ID: 2033964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide for the treatment of patients with myelodysplastic syndromes.
    Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
    Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
    Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
    Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
    Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
    Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alfacalcidol (alpha D3) and calcium in osteoporosis.
    Menczel J; Foldes J; Steinberg R; Leichter I; Shalita B; Bdolah-Abram T; Kadosh S; Mazor Z; Ladkani D
    Clin Orthop Relat Res; 1994 Mar; (300):241-7. PubMed ID: 8131343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.
    Broliden PA; Dahl IM; Hast R; Johansson B; Juvonen E; Kjeldsen L; Porwit-MacDonald A; Sjoo M; Tangen JM; Uggla B; Oberg G; Hellstrom-Lindberg E
    Haematologica; 2006 May; 91(5):667-70. PubMed ID: 16670072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis.
    Kitazaki S; Mitsuyama K; Masuda J; Harada K; Yamasaki H; Kuwaki K; Takedatsu H; Sugiyama G; Tsuruta O; Sata M
    Aliment Pharmacol Ther; 2009 Feb; 29(4):424-30. PubMed ID: 19035979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II trial of vitamin K(2) monotherapy and vitamin K(2) plus 1alpha-hydroxyvitamin D(3) combination therapy for low-risk myelodysplastic syndromes.
    Akiyama N; Miyazawa K; Kanda Y; Tohyama K; Omine M; Mitani K; Ohyashiki K
    Leuk Res; 2010 Sep; 34(9):1151-7. PubMed ID: 20569983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.